Trade Zentalis Pharmaceuticals - ZNTL CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.18 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Zentalis Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 11.21 |
Open* | 10.42 |
1-Year Change* | -52.85% |
Day's Range* | 10.42 - 11.28 |
52 wk Range | 9.56-31.46 |
Average Volume (10 days) | 1.43M |
Average Volume (3 months) | 22.12M |
Market Cap | 732.43M |
P/E Ratio | -100.00K |
Shares Outstanding | 70.77M |
Revenue | N/A |
EPS | -4.65 |
Dividend (Yield %) | N/A |
Beta | 1.58 |
Next Earnings Date | Feb 28, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 11.25 | 0.24 | 2.18% | 11.01 | 11.31 | 10.34 |
Nov 30, 2023 | 11.21 | 0.60 | 5.66% | 10.61 | 11.34 | 10.56 |
Nov 29, 2023 | 10.53 | 0.23 | 2.23% | 10.30 | 11.05 | 10.18 |
Nov 28, 2023 | 10.36 | 0.22 | 2.17% | 10.14 | 10.39 | 9.99 |
Nov 27, 2023 | 10.34 | -0.26 | -2.45% | 10.60 | 10.67 | 10.18 |
Nov 24, 2023 | 10.76 | 0.56 | 5.49% | 10.20 | 10.76 | 10.16 |
Nov 22, 2023 | 10.33 | -0.02 | -0.19% | 10.35 | 10.48 | 10.17 |
Nov 21, 2023 | 10.24 | -0.41 | -3.85% | 10.65 | 10.80 | 10.22 |
Nov 20, 2023 | 10.75 | -0.48 | -4.27% | 11.23 | 11.39 | 10.59 |
Nov 17, 2023 | 11.31 | 0.36 | 3.29% | 10.95 | 11.53 | 10.94 |
Nov 16, 2023 | 11.12 | -0.25 | -2.20% | 11.37 | 11.47 | 10.31 |
Nov 15, 2023 | 11.65 | 0.37 | 3.28% | 11.28 | 12.40 | 11.18 |
Nov 14, 2023 | 11.68 | 0.76 | 6.96% | 10.92 | 11.71 | 10.67 |
Nov 13, 2023 | 10.20 | 0.67 | 7.03% | 9.53 | 10.30 | 9.51 |
Nov 10, 2023 | 9.79 | 0.11 | 1.14% | 9.68 | 9.99 | 9.52 |
Nov 9, 2023 | 9.90 | -0.03 | -0.30% | 9.93 | 10.35 | 9.70 |
Nov 8, 2023 | 9.94 | 0.24 | 2.47% | 9.70 | 10.24 | 9.49 |
Nov 7, 2023 | 10.13 | -1.73 | -14.59% | 11.86 | 12.24 | 9.68 |
Nov 6, 2023 | 12.35 | -5.32 | -30.11% | 17.67 | 17.87 | 12.05 |
Nov 3, 2023 | 17.80 | 1.52 | 9.34% | 16.28 | 17.96 | 16.28 |
Zentalis Pharmaceuticals Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, February 28, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Zentalis Pharmaceuticals Inc Earnings Release Q4 2023 Zentalis Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0.014 |
Revenue | 0 | 0.014 | |||
Total Operating Expense | 227.287 | 164.96 | 118.787 | 46.845 | 23.797 |
Selling/General/Admin. Expenses, Total | 54.553 | 40.941 | 33.886 | 8.459 | 4.876 |
Research & Development | 172.734 | 166.801 | 84.901 | 38.386 | 18.921 |
Operating Income | -227.287 | -164.96 | -118.787 | -46.845 | -23.783 |
Interest Income (Expense), Net Non-Operating | 5.987 | 0.401 | 0.683 | 0.498 | 0.355 |
Other, Net | -0.016 | 0 | |||
Net Income Before Taxes | -221.3 | -164.559 | -118.104 | -46.363 | -23.428 |
Net Income After Taxes | -220.831 | -164.262 | -118.548 | -46.378 | -23.432 |
Minority Interest | 0.307 | 7.368 | 0.707 | 0.715 | 2.365 |
Net Income Before Extra. Items | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Net Income | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Income Available to Common Excl. Extra. Items | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Income Available to Common Incl. Extra. Items | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Diluted Net Income | -236.806 | -158.725 | -117.841 | -45.663 | -21.067 |
Diluted Weighted Average Shares | 52.857 | 42.688 | 28.113 | 34.5015 | 34.5015 |
Diluted EPS Excluding Extraordinary Items | -4.48013 | -3.71826 | -4.19169 | -1.32351 | -0.61061 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -4.48013 | -4.29754 | -4.19169 | -1.32351 | -0.61061 |
Unusual Expense (Income) | 0 | -42.782 | |||
Equity In Affiliates | -16.282 | -1.831 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 103.916 | 64.953 | 51.754 | 54.193 | 63.461 |
Selling/General/Admin. Expenses, Total | 15.664 | 11.369 | 11.138 | 12.012 | 19.636 |
Research & Development | 88.252 | 48.584 | 40.616 | 42.181 | 43.825 |
Operating Income | -103.916 | -64.953 | -51.754 | -54.193 | -63.461 |
Interest Income (Expense), Net Non-Operating | 4.451 | 4.109 | 3.232 | 1.905 | 0.424 |
Other, Net | |||||
Net Income Before Taxes | -99.465 | -60.844 | -48.522 | -52.288 | -63.037 |
Net Income After Taxes | -98.86 | -60.952 | -48.162 | -52.129 | -63.054 |
Minority Interest | 0.037 | 0.043 | 0.013 | 0.099 | 0.035 |
Net Income Before Extra. Items | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Net Income | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Income Available to Common Excl. Extra. Items | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Income Available to Common Incl. Extra. Items | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Diluted Net Income | -112.527 | -63.219 | -54.971 | -54.401 | -68.357 |
Diluted Weighted Average Shares | 60.79 | 59.277 | 58.134 | 56.807 | 51.117 |
Diluted EPS Excluding Extraordinary Items | -1.85108 | -1.0665 | -0.94559 | -0.95765 | -1.33727 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.85108 | -1.01167 | -0.94559 | -0.95765 | -1.33727 |
Unusual Expense (Income) | 0 | 5 | 0 | 0 | |
Equity In Affiliates | -13.704 | -2.31 | -6.822 | -2.371 | -5.338 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 451.933 | 350.77 | 345.104 | 68.891 | 26.677 |
Cash and Short Term Investments | 437.371 | 339.887 | 338.505 | 67.246 | 25.154 |
Cash & Equivalents | 43.069 | 59.714 | 54.951 | 67.246 | 25.154 |
Total Receivables, Net | 6.382 | 0.004 | 0.417 | 0.14 | 0.917 |
Accounts Receivable - Trade, Net | 0.004 | 0.417 | 0.14 | 0.917 | |
Prepaid Expenses | 7.521 | 10.636 | 6.182 | 1.505 | 0.606 |
Total Assets | 539.31 | 454.507 | 365.555 | 87.481 | 40.998 |
Property/Plant/Equipment, Total - Net | 50.078 | 52.839 | 3.619 | 2.836 | 0.26 |
Property/Plant/Equipment, Total - Gross | 52.138 | 53.631 | 3.869 | 3.003 | 0.316 |
Accumulated Depreciation, Total | -2.06 | -0.792 | -0.25 | -0.167 | -0.056 |
Goodwill, Net | 3.736 | 3.736 | 3.736 | 3.736 | 3.736 |
Intangibles, Net | 0 | 8.8 | 8.8 | 8.8 | |
Other Long Term Assets, Total | 12.35 | 9.667 | 4.296 | 3.218 | 1.525 |
Total Current Liabilities | 56.647 | 43.944 | 28.601 | 14.897 | 6.208 |
Accounts Payable | 11.247 | 11.59 | 8.661 | 4.289 | 3.431 |
Accrued Expenses | 45.016 | 31.383 | 19.53 | 10.608 | 2.554 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.384 | 0.971 | 0.41 | 0 | 0.223 |
Total Liabilities | 105.507 | 90.553 | 56.973 | 25.881 | 16.228 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 0.853 | 1.622 | 2.48 | 2.463 | 2.463 |
Minority Interest | 0.221 | 0.528 | 24.795 | 6.821 | 7.536 |
Other Liabilities, Total | 47.786 | 44.459 | 1.097 | 1.7 | 0.021 |
Total Equity | 433.803 | 363.954 | 308.582 | 61.6 | 24.77 |
Redeemable Preferred Stock | 0 | 0 | 0 | 141.706 | 59.83 |
Common Stock | 0.059 | 0.045 | 0.041 | 2.887 | 2.27 |
Retained Earnings (Accumulated Deficit) | -596.365 | -359.559 | -200.834 | -82.993 | -37.33 |
Total Liabilities & Shareholders’ Equity | 539.31 | 454.507 | 365.555 | 87.481 | 40.998 |
Total Common Shares Outstanding | 59.2803 | 45.4908 | 41.0403 | 34.5015 | 34.5015 |
Short Term Investments | 394.302 | 280.173 | 283.554 | ||
Additional Paid-In Capital | 1031.46 | 723.593 | 509.339 | ||
Unrealized Gain (Loss) | -1.353 | -0.125 | 0.036 | ||
Other Current Assets, Total | 0.659 | 0.243 | |||
Long Term Investments | 21.213 | 37.495 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 563.929 | 410.226 | 451.933 | 433.89 | |
Cash and Short Term Investments | 552.986 | 392.519 | 437.371 | 421.726 | |
Cash & Equivalents | 266.558 | 36.28 | 43.069 | 42.551 | |
Short Term Investments | 286.428 | 356.239 | 394.302 | 379.175 | |
Total Receivables, Net | 1.81 | 8.293 | |||
Accounts Receivable - Trade, Net | |||||
Prepaid Expenses | 8.222 | 8.474 | 14.562 | 12.164 | |
Total Assets | 621.444 | 489.342 | 539.31 | 529.193 | |
Property/Plant/Equipment, Total - Net | 43.234 | 44.355 | 50.078 | 50.673 | |
Property/Plant/Equipment, Total - Gross | 45.998 | 47.448 | 52.138 | 52.374 | |
Accumulated Depreciation, Total | -2.764 | -3.093 | -2.06 | -1.701 | |
Goodwill, Net | 3.736 | 3.736 | 3.736 | 3.736 | |
Intangibles, Net | |||||
Other Long Term Assets, Total | 10.545 | 12.122 | 12.35 | 12.859 | |
Total Current Liabilities | 51.759 | 56.358 | 56.647 | 54.061 | |
Accounts Payable | 12.305 | 12.818 | 11.247 | 9.82 | |
Accrued Expenses | 38.832 | 43.115 | 45.016 | 43.893 | |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
Other Current Liabilities, Total | 0.622 | 0.425 | 0.384 | 0.348 | |
Total Liabilities | 98.303 | 103.855 | 105.507 | 100.689 | |
Total Long Term Debt | 0 | 0 | 0 | 0 | |
Deferred Income Tax | 0 | 0.756 | 0.853 | 1.225 | |
Minority Interest | 0.141 | 0.178 | 0.221 | 0.234 | |
Other Liabilities, Total | 46.403 | 46.563 | 47.786 | 45.169 | |
Total Equity | 523.141 | 385.487 | 433.803 | 428.504 | |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
Common Stock | 0.07 | 0.059 | 0.059 | 0.057 | |
Additional Paid-In Capital | 1295.52 | 1045.57 | 1031.46 | 972.111 | |
Retained Earnings (Accumulated Deficit) | -772.111 | -659.584 | -596.365 | -541.394 | |
Other Equity, Total | -0.338 | ||||
Total Liabilities & Shareholders’ Equity | 621.444 | 489.342 | 539.31 | 529.193 | |
Total Common Shares Outstanding | 70.6037 | 59.4423 | 59.2803 | 57.0023 | |
Other Current Assets, Total | 0.911 | 0.94 | 0 | 0 | |
Long Term Investments | 0 | 18.903 | 21.213 | 28.035 | |
Unrealized Gain (Loss) | -0.556 | -1.353 | -2.27 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -237.113 | -166.093 | -118.548 | -46.378 | -23.432 |
Cash From Operating Activities | -163.751 | -154.093 | -86.825 | -39.143 | -24.251 |
Cash From Operating Activities | 1.426 | 0.544 | 0.16 | 0.111 | 0.051 |
Non-Cash Items | 59.453 | -5.101 | 23.702 | 0.617 | 0.308 |
Cash Taxes Paid | 0.012 | 0.02 | 0.018 | 0.015 | 0.004 |
Changes in Working Capital | 13.252 | 16.557 | 7.844 | 6.507 | -1.178 |
Cash From Investing Activities | -114.18 | -18.115 | -284.832 | -0.352 | -0.227 |
Capital Expenditures | -2.548 | -6.107 | -0.758 | -0.352 | -0.227 |
Cash From Financing Activities | 261.043 | 178.521 | 360.439 | 81.83 | 9.472 |
Financing Cash Flow Items | 0 | -1.146 | 18.424 | -0.046 | 0 |
Issuance (Retirement) of Stock, Net | 261.043 | 179.667 | 342.015 | 81.876 | 9.472 |
Net Change in Cash | -16.888 | 6.313 | -11.218 | 42.335 | -15.006 |
Deferred Taxes | -0.769 | 0 | 0.017 | ||
Other Investing Cash Flow Items, Total | -111.632 | -12.008 | -284.074 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -63.262 | -237.113 | -182.129 | -127.629 | -59.237 |
Cash From Operating Activities | -49.283 | -163.751 | -126.422 | -93.223 | -50.196 |
Cash From Operating Activities | 0.36 | 1.426 | 1.067 | 0.692 | 0.344 |
Non-Cash Items | 17.735 | 59.453 | 45.371 | 34.074 | 12.044 |
Changes in Working Capital | -4.019 | 13.252 | 9.269 | -0.36 | -3.347 |
Cash From Investing Activities | 42.121 | -114.18 | -102.286 | -122.304 | 19.796 |
Capital Expenditures | -2.548 | -2.388 | -0.728 | -0.45 | |
Other Investing Cash Flow Items, Total | 42.121 | -111.632 | -99.898 | -121.576 | 20.246 |
Cash From Financing Activities | 0.373 | 261.043 | 211.302 | 210.713 | 1.258 |
Financing Cash Flow Items | 0 | 0 | |||
Issuance (Retirement) of Stock, Net | 0.373 | 261.043 | 211.302 | 210.713 | 1.258 |
Net Change in Cash | -6.789 | -16.888 | -17.406 | -4.814 | -29.142 |
Deferred Taxes | -0.097 | -0.769 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Matrix Capital Management Company, LP | Investment Advisor/Hedge Fund | 19.7707 | 13959973 | 4760000 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 14.3315 | 10119378 | 1661800 | 2023-06-30 | LOW |
Eventide Asset Management, LLC | Investment Advisor | 11.0666 | 7814039 | 936236 | 2023-09-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.9685 | 4920437 | 688558 | 2023-06-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.0323 | 3553312 | 495870 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.4653 | 3152914 | 320891 | 2023-06-30 | LOW |
Capital International Investors | Investment Advisor | 4.4297 | 3127758 | 0 | 2023-06-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 3.7516 | 2648978 | 482312 | 2023-06-30 | LOW |
Avidity Partners Management LP | Hedge Fund | 3.3055 | 2334000 | -595300 | 2023-06-30 | HIGH |
Citadel Advisors LLC | Hedge Fund | 3.0156 | 2129296 | 799303 | 2023-06-30 | LOW |
Decheng Capital Management III (Cayman) LLC | Investment Advisor | 2.9735 | 2099583 | 275000 | 2023-06-30 | LOW |
Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 2.8583 | 2018234 | 531236 | 2023-06-30 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 2.8316 | 1999354 | -11055 | 2023-06-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.7028 | 1908444 | -1451885 | 2023-06-30 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 1.8715 | 1321435 | 31139 | 2023-06-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 1.5737 | 1111150 | -17770 | 2023-06-30 | |
Cormorant Asset Management, LP | Hedge Fund | 1.5508 | 1095000 | 1095000 | 2023-06-30 | LOW |
Woodline Partners LP | Hedge Fund | 1.5507 | 1094974 | -1070577 | 2023-06-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.512 | 1067601 | 171676 | 2023-06-30 | LOW |
Tybourne Capital Management (HK) Limited | Hedge Fund | 1.3617 | 961486 | -670803 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Zentalis Pharmaceuticals Company profile
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Zentalis Pharmaceuticals Inc revenues was not reported. Net loss increased 35% to $158.7M. Higher net loss reflects Research & Development Expense - Balanci increase of 88% to $145.9M (expense), Stock-based Compensation in R&D increase from $7.3M to $20.9M (expense), Selling, General & Administrative Expens increase of 31% to $23.7M (expense).
Industry: | Bio Therapeutic Drugs |
1359 Broadway, Suite 801
NEW YORK
NEW YORK 10018
US
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com